I期临床-话题@MedSci

#I期临床#

570篇内容 | 7049人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653054, encodeId=cec016530541d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：新冠疫苗mRNA-1273 I期临床效果喜人, objectType=article, longId=197638, objectId=522519e63817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=522519e63817, replyNumber=0, likeNumber=62, createdTime=2021-01-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=522519e63817, moduleTitle=NEJM：新冠疫苗mRNA-1273 I期临床效果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=522519e63817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652980, encodeId=27501652980a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, objectType=article, longId=186734, objectId=0fc9186e3483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fc9186e3483, replyNumber=0, likeNumber=58, createdTime=2020-12-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fc9186e3483, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fc9186e3483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653056, encodeId=ef3916530563e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=86, createdTime=2021-01-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652969, encodeId=89071652969f9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=106, createdTime=2020-01-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652996, encodeId=625a16529967e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=57, createdTime=2020-11-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653011, encodeId=dd7816530110a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=83, createdTime=2020-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652961, encodeId=4fd5165296168, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床, objectType=article, longId=183459, objectId=ff15183459d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff15183459d7, replyNumber=0, likeNumber=81, createdTime=2020-10-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff15183459d7, moduleTitle=GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff15183459d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653036, encodeId=461c16530367f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, objectType=article, longId=195493, objectId=6fc619549390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc619549390, replyNumber=0, likeNumber=75, createdTime=2020-06-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc619549390, moduleTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc619549390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652985, encodeId=521e165298560, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始, objectType=article, longId=187515, objectId=788318e515e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788318e515e0, replyNumber=0, likeNumber=65, createdTime=2020-02-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788318e515e0, moduleTitle=基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788318e515e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652940, encodeId=65ec165294041, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=超快速作用胰岛素候选产品At247：已开始I期临床试验, objectType=article, longId=180552, objectId=5f9918055237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f9918055237, replyNumber=0, likeNumber=135, createdTime=2020-06-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f9918055237, moduleTitle=超快速作用胰岛素候选产品At247：已开始I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f9918055237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653000, encodeId=20bd165300061, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nature：新冠mRNA疫苗I期临床试验在美国开展, objectType=article, longId=190285, objectId=6b37190285b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b37190285b3, replyNumber=0, likeNumber=64, createdTime=2020-07-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b37190285b3, moduleTitle=Nature：新冠mRNA疫苗I期临床试验在美国开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b37190285b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652992, encodeId=634b16529929b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=71, createdTime=2020-05-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652954, encodeId=96381652954c1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, objectType=article, longId=182123, objectId=bacc18212334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacc18212334, replyNumber=0, likeNumber=91, createdTime=2020-08-12, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacc18212334, moduleTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacc18212334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653023, encodeId=ba98165302340, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床, objectType=article, longId=193904, objectId=7e121939040f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e121939040f, replyNumber=0, likeNumber=62, createdTime=2021-02-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e121939040f, moduleTitle=新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e121939040f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653035, encodeId=77d01653035f8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成, objectType=article, longId=195277, objectId=a2901952e748, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2901952e748, replyNumber=0, likeNumber=79, createdTime=2021-03-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2901952e748, moduleTitle=全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2901952e748)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652986, encodeId=3b26165298647, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果, objectType=article, longId=187516, objectId=50c918e5164f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50c918e5164f, replyNumber=0, likeNumber=68, createdTime=2020-03-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50c918e5164f, moduleTitle=基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50c918e5164f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653012, encodeId=eda1165301271, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, objectType=article, longId=192309, objectId=fb70192309d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb70192309d8, replyNumber=0, likeNumber=71, createdTime=2020-06-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb70192309d8, moduleTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb70192309d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653044, encodeId=9b77165304419, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, objectType=article, longId=196221, objectId=32501962219e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32501962219e, replyNumber=0, likeNumber=91, createdTime=2020-08-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32501962219e, moduleTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32501962219e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653028, encodeId=afd5165302877, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=68, createdTime=2020-10-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653065, encodeId=23f31653065df, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, objectType=article, longId=198352, objectId=6b7c198352b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7c198352b0, replyNumber=0, likeNumber=65, createdTime=2021-02-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7c198352b0, moduleTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7c198352b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：新冠疫苗mRNA-1273 I期临床效果喜人

2021-01-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据

2020-12-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2021-01-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2020-01-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-11-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2020-12-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床

2020-10-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功

2020-06-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始

2020-02-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

超快速作用胰岛素候选产品At247：已开始I期临床试验

2020-06-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nature：新冠mRNA疫苗I期临床试验在美国开展

2020-07-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-05-26

仁医06 (审核中...)

前往app查看评论内容

#I期临床#

维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究

2020-08-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床

2021-02-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

全球**新冠病毒中和抗体LY-CoV555进入I期临床试验，首批患者给药完成

2021-03-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

基因疗法URO-902治疗膀胱过度活动症：I期临床试验取得积极结果

2020-03-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验

2020-06-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验

2020-08-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-10-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床

2021-02-24

科室
- - 订阅+
  - 更多科室
工具
服务